Dose-related GI symptoms during the rapid titration phase are a well-documented cause of patients quitting GLP-1 therapy (source)
GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying
Wegovy, a higher dose of semaglutide used for weight loss, was recently approved by Health Canada
Retatrutide for weight loss also known as reta, is a next-generation injectable medication currently in Phase 3 clinical trials, showing average weight loss of 28.3%, roughly 70 pounds over 80 weeks at the highest dose
Injury After a Fall : If you hurt yourself, especially if you hit your head, consult a doctor to ensure there are no serious injuries
Fast UK & European Shipping: Secure and discreet shipping available across the UK and Europe